Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bubba Kush is a prominent indica-dominant cannabis strain renowned for its heavy sedative effects and a distinct aromatic profile characterized by notes of coffee and chocolate. Originating in the mid-1990s, it is widely believed to be a cross between a Northern Lights phenotype and an OG Kush hybrid. Its primary therapeutic effects are mediated by high concentrations of delta-9-tetrahydrocannabinol (THC), which acts as a partial agonist at the cannabinoid CB1 and CB2 receptors. In a medical context, Bubba Kush is frequently utilized for the management of chronic pain, insomnia, and stress-related disorders due to its potent muscle-relaxant and anxiolytic properties. As a botanical product, it contains a complex mixture of cannabinoids and terpenes that contribute to its overall pharmacological profile through the entourage effect.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Bubba Kush.